within Pharmacolibrary.Drugs.ATC.L;

model L01EM04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.425,
    Cl             = 5.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0285,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015166666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EM04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase delta and gamma (PI3K-δ and PI3K-γ) isoforms. It is approved for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma after at least two prior therapies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported following oral administration of duvelisib (25 mg twice daily) in adult cancer patients, including CLL/SLL.</p><h4>References</h4><ol><li><p>Flinn, IW, et al., &amp; Horwitz, S (2018). Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. <i>Blood</i> 131(8) 877–887. DOI:<a href=&quot;https://doi.org/10.1182/blood-2017-05-786566&quot;>10.1182/blood-2017-05-786566</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29191916/&quot;>https://pubmed.ncbi.nlm.nih.gov/29191916</a></p></li><li><p>Frustaci, AM, et al., &amp; Montillo, M (2020). Duvelisib for the treatment of chronic lymphocytic leukemia. <i>Expert opinion on pharmacotherapy</i> 21(11) 1299–1309. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2020.1751123&quot;>10.1080/14656566.2020.1751123</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32292084/&quot;>https://pubmed.ncbi.nlm.nih.gov/32292084</a></p></li><li><p>Flinn, IW, et al., &amp; Kahl, B (2018). Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. <i>American journal of hematology</i> 93(11) 1311–1317. DOI:<a href=&quot;https://doi.org/10.1002/ajh.25228&quot;>10.1002/ajh.25228</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30033575/&quot;>https://pubmed.ncbi.nlm.nih.gov/30033575</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EM04;
